Jubilant Pharmova stock | 2026 trend & analyst price target

Jubilant Pharmova

BSE:530019

Rp 864,85

Rp0,00 (0,00%)

864,85 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

Jubilant Pharmova Stock Value

Analysts currently give BSE:530019 a rating of Buy.

Buy

Jubilant Pharmova Company Info

EPS Growth 5Y

-10,37%

Market Cap

Rp136,99 B

Long-Term Debt

Rp21,50 B

Annual earnings

05/16/2026 (E)

Dividend

Rp5,02

Dividend Yield

0,58%

Founded

1978

Industry

Health Care

Country

India

Website

Jubilant Pharmova

ISIN Number

INE700A01033

Website

http://www.jubilantpharmova.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp1.312,50

51.76%

Last Update: 03/30/2026

Analysts: 2

Highest Price Target Rp1.325,00

Average Price Target Rp1.312,50

Lowest Price Target Rp1.300,00

In the last five quarters, Jubilant Pharmova’s Price Target has risen from Rp879,50 to Rp1.298,50 - a 47,64% increase. Two analysts predict that Jubilant Pharmova’s share price will increase in the coming year, reaching Rp1.312,50. This would represent an increase of 51,76%.

Top growth stocks in the health care sector (5Y.)

What does Jubilant Pharmova do?

Jubilant Pharmova Limited operates as an integrated pharmaceutical company that provides pharmaceuticals and healthcare services. The company engages in the manufacture and distribution of a diverse portfolio of products, including active pharmaceutical ingredients (APIs), formulations, and services. Business Segments The company operates through Pharmaceuticals, Life Sciences, and Healthcare Services segments. Pharmaceuticals This segment encompasses the development, manufacturing, and mark...

Business Segments

The company operates through Pharmaceuticals, Life Sciences, and Healthcare Services segments.

Pharmaceuticals

This segment encompasses the development, manufacturing, and marketing of a comprehensive range of pharmaceutical products. The company focuses on prescription medications, with a particular emphasis on complex generics and specialty formulations. By developing products that address unmet medical needs, this segment is positioned as a significant player in the global pharmaceutical landscape.

Life Sciences

This segment provides a wide array of services and products designed for biotechnology and pharmaceutical companies. This includes contract manufacturing, research, and development services, as well as active pharmaceutical ingredients. This segment is integral to the company’s commitment to supporting innovation in healthcare by enabling other companies to accelerate their drug development processes.

Healthcare Services

This segment focuses on the delivery of drugs and therapeutic solutions directly to healthcare providers and patients. This includes clinical support and patient management services for improving treatment outcomes. This segment is dedicated to patient-centric approaches, ensuring that individuals receive the necessary therapies in a timely and effective manner.

Business Strategy

The company’s business strategy is underpinned by a commitment to innovation, quality, and operational excellence. The focus on research and development reflects the company's intent to lead in therapeutic areas that promise significant healthcare improvements. The company continually evaluates emerging trends and technologies to align its product offerings with market demands, ensuring relevance and competitiveness.

To achieve sustainable growth, the company prioritizes strategic partnerships and collaborations, amplifying capabilities through alliances with academic institutions and industry leaders. This approach facilitates the sharing of knowledge and resources, enabling the company to advance in drug discovery and development efforts.

Furthermore, a critical component of the business strategy is geographical expansion. By entering emerging markets and enhancing the company's presence in established regions, the company seeks to diversify its revenue streams and mitigate risks associated with market fluctuations. This global outlook fosters resilience and positions the company to capitalize on growth opportunities across different locales.

Products and Services

The company’s extensive product and service offerings are pivotal to its operations in the pharmaceutical sector. The company's portfolio encompasses:

Active Pharmaceutical Ingredients (APIs): The company manufactures a diverse range of APIs, catering to various therapeutic areas. These APIs are a critical component in the formulation of medications, and the company ensures their quality and reliability to support pharmaceutical companies globally.

Formulations: The company specializes in developing and marketing various pharmaceutical formulations, including oral solids, injectables, and topical applications. The focus on complex generics and specialty drugs enables the company to address specific patient needs while maintaining compliance with stringent regulatory standards.

Contract Research and Manufacturing Services: The life sciences segment provides contract manufacturing and research services to other pharmaceutical and biotechnology companies. This includes drug development support, manufacturing capabilities, and analytical testing services, which are essential in accelerating the drug development process.

Healthcare Solutions: The company delivers integrated healthcare services that encompass clinical support, patient management solutions, and educational resources to healthcare providers. This focus on patient-centric services demonstrates the company’s commitment to improving health outcomes.

Sustainability Initiatives: The company incorporates sustainability into its product development and operational practices. This includes responsible sourcing of raw materials, minimizing waste during production, and ensuring eco-friendly packaging solutions.

Geographical Markets

The company serves various countries and regions, including North America, Europe, Asia, and emerging markets, facilitating access to critical healthcare products for a diverse patient population.

Customers

The company serves a wide range of customer segments, including healthcare providers, pharmaceutical companies, and distributors globally.

Healthcare Providers: This includes hospitals, clinics, and pharmacies that require its pharmaceutical products for patient care.

Pharmaceutical Companies: The company partners with other pharmaceutical firms to provide APIs, contract manufacturing, and research services, enhancing collaborative efforts in the drug development process.

Distributors: The company collaborates with distributors to ensure its products are delivered efficiently to various markets, facilitating access to essential medicines for patients.

Sales and Marketing

The company employs a multifaceted approach to sales and marketing, leveraging digital platforms, personal selling, and strategic partnerships to reach its customers effectively. The company utilizes a variety of distribution channels to ensure its products are accessible across different markets.

Direct Sales: A dedicated sales team engages directly with healthcare providers, promoting the company’s products and services while addressing customer inquiries and needs.

Digital Marketing: The company harnesses digital marketing techniques, including social media campaigns, email newsletters, and online advertisements, to raise awareness about its offerings and reach potential customers globally.

Distribution Partners: Collaborating with distributors, the company ensures that its products are efficiently delivered to various healthcare settings, thereby enhancing its market reach.

Trade Shows and Conferences: The company actively participates in industry trade shows and conferences, showcasing its innovations and building relationships with potential customers and partners.

History

The company was incorporated in 1978. It was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in 2021.

Jubilant Pharmova Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** - Pharmaceuticals: approx. 65% - Life Sciences Ingredients: approx. 25% - Health Solutions: approx. 10% **Top 3 markets:** 1. **USA:** approx. 45% 2. **India:** approx. 25% 3. **Europe:** approx. 15% Jubilant Pharmova Limited generates the majority of its reven...

At which locations are the company’s products manufactured?

**Production sites of Jubilant Pharmova Limited:** 1. **India:** Multiple production facilities, including in Nanjangud (Karnataka), Roorkee (Uttarakhand), and Gajraula (Uttar Pradesh). 2. **USA:** Production facilities in Spokane, Washington. 3. **Canada:** Production facilities in Kirkland, Québe...

What strategy does Jubilant Pharmova pursue for future growth?

**Revenue Growth:** Estimated at 8-10% annually (based on historical data and industry trends until 2023) **Focus on Research and Development:** Jubilant Pharmova Limited has increased its investment in research and development in recent years to develop innovative pharmaceutical products and expan...

Which raw materials are imported and from which countries?

**Main raw materials:** Active pharmaceutical ingredients (APIs), chemicals, excipients **Countries of origin:** China, India, USA, Germany Jubilant Pharmova Limited imports a variety of raw materials necessary for the production of pharmaceutical products. The main raw materials include active ph...

How strong is the company’s competitive advantage?

**Market Share:** 8% (estimated, 2026) **R&D Expenses:** 7.5% of revenue (2025) **EBITDA Margin:** 18% (2025) Jubilant Pharmova Limited has established a solid competitive advantage in the pharmaceutical industry. The company benefits from a diversified product portfolio that includes both...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 35% (estimated, 2026) **Insider Buys/Sells:** No significant changes (estimated, 2026) The institutional investor share in Jubilant Pharmova Limited is estimated to be around 35%. This indicates that a significant portion of the shares are held by large investmen...

What percentage market share does Jubilant Pharmova have?

**Market share of Jubilant Pharmova Limited:** Estimate: 3-5% (2026) **Main competitors and their market share:** 1. **Sun Pharmaceutical Industries Ltd.:** 8-10% 2. **Dr. Reddy's Laboratories Ltd.:** 7-9% 3. **Cipla Ltd.:** 6-8% 4. **Aurobindo Pharma Ltd.:** 5-7% 5. **Lupin Ltd.:** 4-6% **Mo...

Is Jubilant Pharmova stock currently a good investment?

**Revenue Growth:** 8.5% (2025) **Profit Growth:** 10.2% (2025) **Research and Development Investments:** 12% of revenue (2025) Jubilant Pharmova Limited achieved solid revenue growth of 8.5% in 2025, indicating successful expansion of its product range and a strong market presence. The 10.2% profi...

Does Jubilant Pharmova pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (estimated for 2026) **Dividend History:** Regular payouts in recent years Jubilant Pharmova Limited has regularly distributed dividends to its shareholders in recent years. The dividend yield for the year 2026 is estimated to be around 2.5%. This estimate is based on h...

New support ticket

Explore

Jubilant Pharmova Stock Value

Jubilant Pharmova Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Jubilant Pharmova do?

Jubilant Pharmova Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Jubilant Pharmova Stock Value

Jubilant Pharmova Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Jubilant Pharmova do?

Jubilant Pharmova Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.